Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ixazomib for Desensitization in Kidney Transplantation

Trial Profile

Ixazomib for Desensitization in Kidney Transplantation

Phase of Trial: Phase II

Latest Information Update: 14 Jan 2019

At a glance

  • Drugs Ixazomib (Primary)
  • Indications Graft-versus-host disease
  • Focus Proof of concept; Therapeutic Use
  • Acronyms IXADES
  • Most Recent Events

    • 04 Jan 2019 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
    • 04 Jan 2019 Planned primary completion date changed from 1 May 2019 to 1 May 2020.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top